Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Theratechnologies' commercial partner, an affiliate of Sanofi, has submitted a marketing authorization application (MAA) to register tesamorelin in Brazil with the National Health Surveillance Agency (ANVISA), a division of its Ministry of Health.
Subscribe to our email newsletter
Tesamorelin is intended as a treatment for excess abdominal fat in HIV-infected patients with lipodystrophy.
Earlier in December 2010, Theratechnologies has given license to an affiliate of Sanofi to commercialize for tesamorelin in Latin America, Africa and the Middle East.
Theratechnologies president and CEO John-Michel Huss said this is the first regulatory application for tesamorelin in Latin America.